- Home
- ADCT vs FULC Comparison
ADCT vs FULC Comparison
Compare ADCT & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- FULC
- Stock Information
- Founded
- ADCT 2011
- FULC 2015
- Country
- ADCT Switzerland
- FULC United States
- Employees
- ADCT N/A
- FULC N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- ADCT Health Care
- FULC Health Care
- Exchange
- ADCT Nasdaq
- FULC Nasdaq
- Market Cap
- ADCT 454.5M
- FULC 468.1M
- IPO Year
- ADCT 2020
- FULC 2019
- Fundamental
- Price
- ADCT $4.40
- FULC $11.29
- Analyst Decision
- ADCT Strong Buy
- FULC Strong Buy
- Analyst Count
- ADCT 6
- FULC 7
- Target Price
- ADCT $7.60
- FULC $12.71
- AVG Volume (30 Days)
- ADCT 759.6K
- FULC 814.7K
- Earning Date
- ADCT 11-10-2025
- FULC 10-29-2025
- Dividend Yield
- ADCT N/A
- FULC N/A
- EPS Growth
- ADCT N/A
- FULC N/A
- EPS
- ADCT N/A
- FULC N/A
- Revenue
- ADCT $75,209,000.00
- FULC N/A
- Revenue This Year
- ADCT $11.78
- FULC N/A
- Revenue Next Year
- ADCT $4.83
- FULC N/A
- P/E Ratio
- ADCT N/A
- FULC N/A
- Revenue Growth
- ADCT 6.35
- FULC 2752.05
- 52 Week Low
- ADCT $1.05
- FULC $2.32
- 52 Week High
- ADCT $4.80
- FULC $12.19
- Technical
- Relative Strength Index (RSI)
- ADCT 58.45
- FULC 65.12
- Support Level
- ADCT $3.95
- FULC $10.75
- Resistance Level
- ADCT $4.29
- FULC $12.05
- Average True Range (ATR)
- ADCT 0.28
- FULC 0.76
- MACD
- ADCT 0.03
- FULC 0.30
- Stochastic Oscillator
- ADCT 89.02
- FULC 81.71
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.